نتائج البحث

Methuosis Inducer SGI-1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer.

• Authors : Luo Y; The Key Laboratory of Urinary Tract Tumors and Calculi, Department of Urology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, 361003, P. R. China.; Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, 400016, P. R. China.

Subjects: Everolimus*/Everolimus*/Everolimus*/pharmacology ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/drug therapy ; Kidney Neoplasms*/Kidney Neoplasms*/Kidney Neoplasms*/metabolism

• Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) [Adv Sci (Weinh)] 2024 Oct; Vol. 11 (38), pp. e2404693. Date of Electronic Publication: 2024 Aug 09.Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844

تفاصيل العنوان

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

• Authors : National Cancer Institute (NCI)

• Source: A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor

تفاصيل العنوان

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (S0931)

• Authors : National Cancer Institute (NCI)

• Source: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III StudyGulati S, Tangen C, Ryan CW, Vaishampayan UN, Shuch BM, Barata PC, Pruthi DK,

تفاصيل العنوان

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

• Source: A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and

تفاصيل العنوان

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

• Authors : Eisai Inc.; Yousef Zakharia, Clinical Assistant Professor

• Source: Proof of Concept for Lenvatinib and Everolimus Prior to Nephrectomy in Eligible Patients With Local and Metastatic Renal Cell Carcinoma (RCC)

تفاصيل العنوان

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

• Source: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and

تفاصيل العنوان

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

• Authors : Merck Sharp & Dohme LLC

• Source: A Randomized, Open-Label (Formerly Double-Blind), Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With

تفاصيل العنوان

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

• Authors : Emberley E; Calithera Biosciences, Inc., South San Francisco, CA, United States of America.; Pan A

Subjects: Anilides/Anilides/Anilides/*administration & dosage ; Benzeneacetamides/Benzeneacetamides/Benzeneacetamides/*administration & dosage ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy

• Source: PloS one [PLoS One] 2021 Nov 03; Vol. 16 (11), pp. e0259241. Date of Electronic Publication: 2021 Nov 03 (Print Publication: 2021).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

• Authors : Jun GUO, Associate Director of Peking University Cancer Hospital

• Source: A Multicenter, Randomized Controlled Study Comparing Vorolanib Tablets Plus Everolimus With Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed

تفاصيل العنوان

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

• Authors : Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK. .; Choueiri TK

Subjects: Anilides/Anilides/Anilides/*therapeutic use ; Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*blood ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*blood

• Source: BMC cancer [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. Date of Electronic Publication: 2021 Aug 07.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان